GFM
MBX

GF Fund Management’s MBX Biosciences MBX Stock Holding History

GF Fund Management’s Portfolio MBX Stock Details MBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$52.5K Sell
952
-57
-6% -$1.99K ﹤0.01% 384
2026
Q1 		$30.1K Buy
1,009
+127
+14% +$4.32K ﹤0.01% 455
2025
Q4 		$27.8K Buy
+882
New +$21.4K ﹤0.01% 473

Other funds holding MBX

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
NA
NVP Associates Menlo Park, California $328M AUM 166.51% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

GF Fund Management's MBX Position: Q2 2026 in Review

GF Fund Management reduced its MBX Biosciences (MBX) stake by 5.6% in Q2 2026, selling an estimated $1.99K and leaving 952 shares worth $52.5K. The position accounts for ﹤0.01% of the portfolio, ranked #384.

GF Fund Management first reported a position in MBX in Q4 2025 and has held it in 3 quarters since. 173 funds tracked by Wall St. Rank hold MBX as of Q2 2026.

  • GF Fund Management held 952 shares of MBX Biosciences worth $52.5K as of Q2 2026.
  • GF Fund Management sold 57 MBX Biosciences shares in Q2 2026, an estimated $1.99K.
  • MBX Biosciences made up ﹤0.01% of GF Fund Management's portfolio in Q2 2026, its #384 holding.
  • GF Fund Management first reported a position in MBX Biosciences in Q4 2025 and has held it in 3 quarters since.
  • 173 funds tracked by Wall St. Rank held MBX Biosciences as of Q2 2026.

Based on GF Fund Management's 13F filing for Q2 2026, filed 7 Aug 2026.